Medicare Covers Photodynamic Therapy for Occult Lesions of AMD

Why This Topic Matters

Coverage policy changes can affect whether services are reimbursable, how claims are processed, and how practices manage patient financial responsibility. This update is especially important for retina practices and coders because it changes the Medicare landscape for a commonly discussed ophthalmic treatment and highlights the difference between national policy and local carrier implementation.

Article Sections

1. Medicare coverage update

   Introduces the Medicare policy change and its timing, along with the general treatment area involved. It also notes the broader administrative context for the coverage decision.

2. Historical background and provider reaction

   Summarizes prior Medicare positions and the way specialty practitioners responded over time. It also reflects comments from ophthalmology and retinal care professionals about the change.

3. Coverage criteria for the updated indications

   Outlines the general conditions described in the national coverage policy for the newly covered lesion categories. The section focuses on the types of documentation and clinical characteristics referenced by the article.

4. Local carrier implementation issues

   Discusses how local Medicare carrier policies may affect real-world reimbursement even after a national policy change. It highlights operational concerns for practices submitting claims.

5. Coverage context for other lesion types and diagnoses

   Reviews the article’s broader discussion of photodynamic therapy coverage in related retinal conditions. It distinguishes the updated AMD policy from other covered and noncovered uses in general terms.